Sugi Predict

Sugi Predict / Compounds / SCHEMBL205089

SCHEMBL205089

SCHEMBL205089

COC(=O)c1ccc(Br)c(C)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 2/20 0.60
▸ TDP1 Q9NUW8 1/20 0.53
▸ CA1 P00915 3/20 0.53
▸ CA2 P00918 3/20 0.53
▸ CA12 O43570 2/20 0.53
▸ CA7 P43166 2/20 0.53
▸ CA9 Q16790 2/20 0.53
▸ CA14 Q9ULX7 2/20 0.53
▸ XDH P47989 1/20 0.53
▸ CHRNA1 P02708 1/20 0.51
▸ CHRNG P07510 1/20 0.51
▸ CHRNB1 P11230 1/20 0.51
▸ CHRNB2 P17787 1/20 0.51
▸ SLC6A2 P23975 1/20 0.51
▸ CHRNB4 P30926 1/20 0.51
▸ SLC6A4 P31645 1/20 0.51
▸ CHRNA3 P32297 1/20 0.51
▸ CHRNA4 P43681 1/20 0.51
▸ SLC6A3 Q01959 1/20 0.51
▸ CHRND Q07001 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9563420 0.93 NOTUM (0.54) NOTUMTDP1CA1CA2CA12
SCHEMBL2651678 0.86 NOTUM (0.48) NOTUMTDP1CA1CA2CA12
SCHEMBL15780793 0.86 CA1 (0.53) NOTUMTDP1CA1CA2CA12
SCHEMBL502520 0.85 NOTUM (0.60) NOTUMTDP1CA1CA2CA12
SCHEMBL29976975 0.85 NOTUM (0.60) NOTUMTDP1CA1CA2CA12
SCHEMBL12151586 0.84 NOTUM (0.64) NOTUMTDP1CA1CA2CA12
SCHEMBL30029511 0.82 MAPT (0.63) NOTUMTDP1CA1CA2CA12
SCHEMBL35783 0.82 MAPT (0.63) NOTUMTDP1CA1CA2CA12
SCHEMBL31700926 0.81 CA12 (0.59) CA1CA2CA12CA7CA9
SCHEMBL137202 0.81 CA12 (0.59) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1075 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116332976-B Nuclear magnetic resonance imaging contrast agent Hyp-DOTA-Gd and preparation method and application thereof 武汉大学中南医院 2025-04-08 — — CN claimed
CN-117430624-A Chemical cross-linking agent and preparation method and application thereof 中国科学院大连化学物理研究所 2024-01-23 — — CN claimed
CN-116332976-A Nuclear magnetic resonance imaging contrast agent Hyp-DOTA-Gd and preparation method and application thereof 武汉大学中南医院 2023-06-27 — — CN claimed
US-7659421-B2 Phenylboronic acid compounds and intermediates and processes for the preparation thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-02-09 — — US claimed
EP-1768988-B1 NOVEL PHENYL-BORONIC ACID DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF GALDERMA RES & DEV (FR) 2009-01-28 — — EP claimed
US-20070015931-A1 Novel phenylboronic acid compounds and intermediates and processes for the preparation thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-01-18 — — US claimed
CN-122029148-A N-phenyl-3- (2, 5-dioxopyrrolidin-1-yl) propionamide derivatives and similar compounds as DUX4 inhibitors for the treatment of, for example, neuromuscular diseases 阿勒泰治疗公司 2026-05-12 — — CN disclosed
US-20260125390-A1 SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME KURA ONCOLOGY INC (US) 2026-05-07 — — US disclosed
US-20260125367-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2026-05-07 — — US disclosed
EP-4727591-A1 SMARCA2 DEGRADERS AND USES THEREOF Astrazeneca AB (SE) 2026-04-22 — — EP disclosed
EP-4720073-A1 SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS Kura Oncology, Inc. (US) 2026-04-08 — — EP disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 — — US disclosed
EP-4676922-A1 BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS Astrazeneca AB (SE) 2026-01-14 — — EP disclosed
WO-1993006084-A1 BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS GLAXO GROUP LIMITED (GB) 1993-04-01 — — WO disclosed
EP-0533267-A1 Benzanilide derivatives as 5-HT1D antagonists GLAXO GROUP LIMITED (GB) 1993-03-24 — — EP disclosed
EP-0533266-A1 Benzanilide derivatives as 5-HT1D antagonists GLAXO GROUP LIMITED (GB) 1993-03-24 — — EP disclosed
EP-0206635-B1 PREPARATION OF 3-AMINO-4-HYDROXYBENZOIC ACIDS THE DOW CHEMICAL COMPANY (US) 1989-11-15 — — EP disclosed
US-4835306-A Preparation of 3-amino-4-hydroxybenzoic acids THE DOW CHEMICAL COMPANY (US) 1989-05-30 — — US disclosed
EP-0296749-A1 (Substituted aralkyl) heterocyclic compounds ZENECA LIMITED (GB) 1988-12-28 — — EP disclosed
EP-0206635-A1 Preparation of 3-amino-4-hydroxybenzoic acids THE DOW CHEMICAL COMPANY (US) 1986-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125390-A1 SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME FDPS, PCTP, MTTP NOTUM 185/4885TDP1 2694/4885CA1 1383/4885
US-20070015931-A1 Novel phenylboronic acid compounds and intermediates and processes for the preparation thereof VDR, CYP24A1, CYP2R1 NOTUM 2702/4885TDP1 4591/4885CA1 2378/4885
US-20260125367-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, MALT1, BCL6 NOTUM 2860/4885TDP1 3561/4885CA1 31/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 NOTUM 2446/4885TDP1 1465/4885CA1 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.